Prevention of Long Covid Syndrome
NCT05793736, Not applicable, Completed, University of Cagliari
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Prevention of Long Covid Syndrome | ClinicalTrials.gov |
| NCT number | NCT05793736 | ClinicalTrials.gov |
| Status | Completed | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 17 participants, actual | ClinicalTrials.gov |
| Lead sponsor | University of Cagliari | ClinicalTrials.gov |
| Conditions | Post-Acute COVID-19 Syndrome, Biofeedback, Psychology, Quality of Life, Depressive Symptoms, Fatigue, Anxiety, Pain, Cognitive Symptom | ClinicalTrials.gov |
| Interventions | Biofeedback training, Treatment as usual | ClinicalTrials.gov |
| First posted | 2023-03-31 | ClinicalTrials.gov |
| Last updated | 2024-05-13 | ClinicalTrials.gov |
Registered outcomes 13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Patient Health Questionnaire-9 (PHQ-9) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | short self-administered tool used for screening, diagnosis, monitoring and measuring the severity of depression. It's composed of 9 items that correspond to the symptoms of major depression according to DSM-IV. The score has a range between 0 and 27. Scores between 0 and 9 indicate the presence of a sub-threshold depression. The score of 10 is indicated as the point at which the sensitivity and specificity of the instrument are recognized as optimal for highlighting depressions of clinical relevance | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Brief Fatigue Inventory (BFI) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | The Brief Fatigue Inventory (BFI) is a brief screening tool designed to assess the severity and impact of fatigue on daily functioning. | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Short Form Health Survey (SF-12) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | The Short Form Health Survey (SF-12), brief version of SF-36 questionnaire, made up of twelve questions, includes the following dimensions: physical activity, disturbance in physical health, physical condition, self-assessment of health status, vitality, social activity and mental health. Higher SF-12 scores recorded a greeting and QoL performance. | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Matrix test (Spinnler H, Tognoni G., 1987) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | Evaluates the indicators of selective attention | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Trail Making Test (Giovagnoli et al.,1996) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | Evaluates cognitive functions such as cognitive flexibility and inhibitory control and attention | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Digit Span (Orsini et al., 1987; Mondini et al., 2003) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | Evaluate verbal short-term memory and working memory | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Stroop Test (Caffarra et al.; 2002) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | Evaluates selective attention, the processes of inhibition of irrelevant information and cognitive flexibility | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Frontal Assessment Battery - FAB (Dubois et al.; 2000) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | It is a functionality screening battery global executive performance by means of a series of cognitive and behavioral tests | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Rey's Word Test (Caltagirone et al. 1995) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | Evaluates long-term memory, semantic memory, specifies in which phase of the mnemonic process the deficit is | ClinicalTrials.gov |
| Primary | Change in Checklist on tolerability, possible side effects after the biofeedback session | At the end of each biofeedback session | Checklist on tolerability, possible side effects after the biofeedback session | ClinicalTrials.gov |
| Primary | Intervention satisfaction questionnaire | T1 (5weeks) | Intervention satisfaction questionnaire | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Visual Analog Scale VAS (Scott Huskisson, 1976) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | Allows you to have a visual representation of the amplitude of the pain perceived by the person ache | ClinicalTrials.gov |
| Primary | Change from Baseline to 5 weeks and to 9 weeks in Self-Rating Anxiety Scale (SAS) score | T0 (0 weeks); T1 (5weeks); T2 (9 weeks) | SAS is a 20-item self-report assessment device built to measure anxiety levels, based on scoring in 4 groups of manifestations: cognitive, autonomic, motor and central nervous system symptoms. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 0
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Digit Span Test | Primary outcome | ConductCognition |
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)